SERAPINO.416 318 SIZN4 FORM PTO-1449 (Modified) ATTY. DOCKET NO.: V0179/7000 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S APPLICANT: Wanker et al. INFORMATION DISCLOSURE STATEMENT FILING DATE: Herewith GROUP: Not yet assigned **U.S. PATENT DOCUMENTS** Exam Ref Sub FILING DATE Init Des Document No. Date Name Class Class If Appropriate OC 5,234,814 08/10/93 Card et al. 435 7.21 06/01/89 03/03/98 oc 5,723,301 Burke et al. 435 7.1 11/03/95 **FOREIGN PATENT DOCUMENTS** Pub. Country & Sub Translation Doc. No. (11) Date (43) Class Class Yes EP 0 206302A2 30.12.86 EP 0 293 249 A1 30.11.88 22.07.98 EP 0 854 364 A1 ÛĊ WO95/29243 02.11.95 WO96/12544 02.05.96 WO96/28471 19.09.96 WO97/17445 15.05.97 **OTHER ART** (Including Author, Title, Date, Pertinent Pages, Publication, Etc.) Kisilevsky et al., "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: 00 Implications for Alzheimer's disease", (2/95), pp. 143-148, Nature Medicine, Vol. 1, No. 2. Trottler et al., "Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant 1C Cerebellar ataxias", (11/23/85), pp. 403-406, *Nature* Vol. 378. Gutekunst et al., "Identification and localization of huntingtin in brain and human lymphoblastoid cell lines 00 with anti-fusion protein antibodies", (9/95), pp. 8710-8714, Pro. Natl. Acad. Sci. USA Vol. 92 Neurobiology. M.F. Perutz, "Glutamine repeats and inherited neurodegenerative diseases: molecular aspects", (1996) pp. 848-OC 858, MRC Laboratory of Molecular Biology. Muy show **EXAMINER** DATE CONSIDERED 07/23/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449(Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

APPLICANT: Wanker et al.

FILING DATE: Herewith

GROUP: Not yet assigned

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

Mangiarini et al., "Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive		
neurological phenotype in transgenic mice", (11/01/96), pp. 493-506, Cell, Vol. 87.		
Stott et al., "Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative		
Diseases", (7/95), pp. 6509-6513, Pro. Natl. Acad. Sci. USA, Vol. 92, Biochemistry.		
Merlini et al., "Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of		
amyloidogenesis", (3/95), pp. 2959-2963, Proc. Natl. Acad. Sci. USA, Vol. 92, Medical Sciences.		
Scherzinger, et al., "Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in		
vitro and in vivo", (8/8/97), pp. 549-558, Cell, Vol. 90.		
Davies et al., "Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice		
Transgenic for the HD mutation", (8/8/97), pp. 537-548, Cell, Vol. 90.		
Derwent, "Nucleic acid fragments associated with spinocerebellar ataxis type 2-contain increased number of		
CAG repeat region compared to normal gene", (5/7/98), XP-002101183.		
Tateishe et al., "Removal of causative agent of creutzefeldt-jakob disease (CJD) through membrane filtration method",		
(1993), pp. 357-362, Membrane, 18(6).		

EXAMINER Claufshy	DATE CONSIDERED	07/23/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant